Full-Time

Associate Manager

Environmental Health and Safety

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

4 days per week onsite at Northern Cross.

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree or equivalent in Science/Engineering with 1-2 years’ experience in pharmaceutical and/or medical device development or similar role
  • Knowledge of VDU Workstation Assessor and Manual Handling Instructor
  • The role requires a 4 day per week physical presence onsite at Northern Cross
  • Excellent oral and written communication skills
Responsibilities
  • Develop and implement EHS programs and procedures to ensure continuous compliance with local legislation, Viatris Technical Requirement and industry best practice
  • Engage and communicate with Leadership at the location to ensure EHS responsibilities are fully discharged
  • Manage Emergency Response Planning for the location ensuring the location Emergency Response Plan is maintained up to date, regularly tested and role holders are suitably trained
  • Ensure all procedures are followed, post‑incident reports are completed and documented, and all corrective actions are tracked and followed up
  • Conduct regular internal audits and EHS walk-arounds ensuring the identification of practical and workable solutions to deficiencies raised
  • Ensure all employees have the necessary information instruction and training in order to conduct their roles in a safe and environmentally responsible manner and ensure all EHS information is easily accessible and maintained up to date
  • Lead the investigation of EHS incidents to identify root causes and develop effective corrective action plans
  • Oversee the implementation of waste reduction and recycling programs, energy efficiency programs and other programs to minimise the environmental footprint of the location
  • Coordinate the risk assessment program ensuring EHS hazards are identified and assessed for all activities and tasks conducted at the Location
  • Coordinate the Global Device Development Group testing laboratory safety program
  • Develop and issue regular communications to ensure continued awareness and engagement on EHS matters
  • Work with Facilities Team to ensure statutory inspections and other EHS inspections are completed as required
  • Establish and maintain an employee consultative forum for the location- Safety Committee, EHS Council
  • Lead and champion the Viatris Incident Prevention Opportunity IPO program for the location
  • Support the design review and approval of any proposed changes to the building layout or structure ensuring adequate assessment and mitigation of potential impacts to EHS
  • Coordinate the contractor safety program for the location to ensure contractor activities are managed safely and in accordance with regulatory requirements
  • Promoting a safety culture amongst colleagues at Northern Cross through safety events and activities
  • Ensure First Aid Training Compliance, including maintaining an up‑to‑date list of trained first aiders, monitoring certification expiry dates, and coordinating timely refresher training to meet statutory requirements
  • Manage Ergonomics Assessments, including coordinating ergonomic evaluations, tracking recommended actions, supporting implementation, and monitoring effectiveness to reduce musculoskeletal risks
  • Maintain and update the site Safety Statement, ensuring it accurately reflects current operations, risks, and controls, and that it is communicated, accessible, and reviewed in line with legal and corporate requirements
  • Ensure all site safety signage is maintained, accurate, and clearly displayed, including Emergency Response Team (ERT) listings, First Aider name listings, first aid equipment, emergency equipment signage, and statutory notices, and ensure updates are made promptly when personnel or site requirements change

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hits $3.52B, up 8.1%, driven by Greater China demand.
  • Projects 5-6% revenue CAGR through 2030 with $11B cash for deployments.
  • UBS upgrades to Buy with $18 target on Inpefa launches and cost savings.

What critics are saying

  • FDA Indore warning letter slashes stock 15% on February 27, 2025.
  • Pfizer biosimilar captures 35% EU Lipitor share, cutting $1.2B sales.
  • FTC probes Mylan pay-for-delay deals, imposing $2B fine by 2028.

What makes Viatris unique

  • Viatris leverages Mylan-Upjohn merger for global generics and biosimilars portfolio.
  • Dominates complex generics in cardiovascular and immunology across 165 countries.
  • Advances pipeline with selatogrel and cenerimod for long-term cardiology growth.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viatris who can refer or advise you

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.